Clomipramine: Difference between revisions
From Glioblastoma Treatments
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 13: | Line 13: | ||
|category=Repurposed Drugs | |category=Repurposed Drugs | ||
|links= | |links= | ||
}} | |||
|toxicity_level=4 | |||
}} | }} | ||
Revision as of 08:01, 27 March 2024
| Property | Information |
|---|---|
| Drug Name | Clomipramine (Chlorimipramine) |
| FDA Approval | Yes (for depression and obsessive-compulsive neuroses) |
| Used for | High-grade gliomas, including glioblastoma multiforme (GBM) |
| Clinical Trial Phase | Initial findings reported; further research needed |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Known for its general tolerability; specific studies on glioma treatment might reveal more details |
| OS without | Median survival with traditional treatments like BCNU alone reported at 11 months |
| OS with | When combined with chloroquine, median survival extended to 25-33 months according to early studies |
| PFS without | Not specified |
| PFS with | Improvement in PFS-6 when combined with traditional chemotherapy agents |
| Usefulness Rating | 3 |
| Usefulness Explanation | Not specified |
| Toxicity Level | Not specified |
| Toxicity Explanation | Not specified |
Notes: Clomipramine, an antidepressant, has shown promise in treating high-grade gliomas by selectively depressing mitochondrial function in glioma cells, leading to apoptosis. Initial studies suggest potential efficacy in extending survival when combined with chemotherapy, though further detailed research is essential to validate these findings and explore mechanisms like autophagy inhibition.
From Ben Williams Book: Not specified
Loading comments...
|toxicity_level=4 }}
